Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E34.19 EPS (ttm)1.00 Insider Own0.04% Shs Outstand6.07B Perf Week1.90%
Market Cap207.99B Forward P/E12.30 EPS next Y2.79 Insider Trans-1.32% Shs Float6.06B Perf Month10.61%
Income6.18B PEG5.48 EPS next Q0.67 Inst Own71.70% Short Float0.57% Perf Quarter10.47%
Sales53.24B P/S3.91 EPS this Y5.20% Inst Trans-0.04% Short Ratio1.34 Perf Half Y0.39%
Book/sh9.80 P/B3.50 EPS next Y8.96% ROA4.20% Target Price37.95 Perf Year16.25%
Cash/sh2.94 P/C11.65 EPS next 5Y6.24% ROE11.60% 52W Range27.69 - 36.35 Perf YTD6.55%
Dividend1.28 P/FCF31.59 EPS past 5Y3.30% ROI7.80% 52W High-5.56% Beta0.98
Dividend %3.74% Quick Ratio1.00 Sales past 5Y-2.80% Gross Margin76.60% 52W Low23.96% ATR0.46
Employees96500 Current Ratio1.30 Sales Q/Q-3.00% Oper. Margin16.90% RSI (14)80.48 Volatility1.24% 1.38%
OptionableYes Debt/Eq0.71 EPS Q/Q600.90% Profit Margin13.50% Rel Volume0.66 Prev Close34.26
ShortableYes LT Debt/Eq0.53 EarningsJan 31 BMO Payout101.50% Avg Volume25.61M Price34.32
Recom2.40 SMA205.32% SMA506.14% SMA2003.99% Volume14,850,339 Change0.19%
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Feb-27-17 03:03PM  Drugmakers pledge restraint, but prices will still soar
01:22PM  Why You Shouldn't Look Down On Your Depressed Colleagues at Forbes
10:38AM  Pfizers Products with Falling Revenues in 4Q16
09:54AM  [$$] VC Profile: OrbiMed Funds Novel Attacks on Cancer at The Wall Street Journal
09:08AM  Understanding Pfizers Growth Contributors in 4Q16
07:38AM  Pfizers Innovative Health and Essential Health in 4Q16
07:35AM  Merck & Co.s Valuation after Its 4Q16 Earnings
07:15AM  Biogen alums team up to launch Waltham biotech, with backing from Henri Termeer at bizjournals.com
Feb-25-17 09:25AM  Details Still Missing on Republicans' 'Once in a Generation' Tax Plan
Feb-24-17 06:41PM  Pfizer subpoenaed in U.S. over patient assistance plans Reuters
05:30PM  Pfizer Subpoenaed in DOJ Investigation of Drugmaker Charity Connections
04:53PM  Pfizers Valuation after Its 4Q16 Earnings Release
01:09PM  Pfizer Prices $1,065,000,000 Debt Offering Business Wire
11:05AM  Novartis Cancer Drug Zykadia Gets Priority Review at Investopedia
08:45AM  Pfizer Inc. -- Moody's assigns A1 to Pfizer's notes; stable outlook at Moody's
07:39AM  Performance of Eli Lilly & Co.s Business Segments in 4Q16
07:27AM  Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
Feb-23-17 06:29PM  Dow Jones Leads Market Gains on Thursday
05:39PM  United Therapeutics feels squeeze from increased pulmonary hypertension competition at bizjournals.com
05:06PM  PFIZER INC Files SEC form 8-K, Financial Statements and Exhibits
04:54PM  PFIZER INC Files SEC form 10-K, Annual Report
04:36PM  Dow logs 10th straight record, but Nasdaq stumbles a second day at MarketWatch
04:15PM  Ronald E. Blaylock Elected to Pfizers Board of Directors Business Wire
04:01PM  Johnson & Johnson, Pfizer Lead DJIA Higher on Thursday
Feb-22-17 06:21PM  Who Could Buy Bristol-Myers Squibb? at Motley Fool
05:08PM  Pfizer's Leukemia Candidate Gets Priority Review in U.S.
04:41PM  Pfizer Inc. (PFE) Invest For Attractive Valuation And The 4% Dividend Yield at Insider Monkey
02:02PM  Manufacturing Delay Of Generic Drug From Pfizer Inc. (PFE) A Relief For Teva Pharmaceutical Industries Ltd (ADR) (TEVA) at Insider Monkey
01:51PM  Goldman Says Buy Health-Care, Retail Volatility Before Trump Address at The Wall Street Journal
12:25PM  Why Spark's CEO says 2017 may be a 'historic year' for his gene therapy company at bizjournals.com
09:08AM  Merck & Co.s Segment-Wise Revenues for 4Q16
08:23AM  World's Biggest Drugmaker Quits London and Swiss Listings at TheStreet
07:54AM  Early movers: TOL, DISH, SIX, TRCO, FSLR, & more at CNBC
03:33AM  Pfizer Quits London and Swiss Listings, Says 'Limited Liquidity' in European Trading
02:07AM  Factor Xa's Win Billions of Dollars in Sales From Warfarin at Motley Fool
01:57AM  Better Buy: Pfizer Inc. vs. Merck & Co. Inc. at Motley Fool
Feb-21-17 12:37PM  Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug
11:35AM  Momenta shares plunge after supplier receives warning letter from FDA on multiple sclerosis drug at CNBC
11:11AM  Heres What The Latest Pain Therapeutics, Inc. (PTIE) Update Means at Insider Monkey
10:57AM  Boeing, GE and Oracle CEOs Support Border Adjustment Tax in Letter to Congress at TheStreet
10:47AM  Execs from Boeing, Pfizer Send Letter Backing House GOP Tax Plan
08:00AM  Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration Business Wire
Feb-19-17 07:54AM  A Billionaire Recently Bought Pfizer Stock -- and So Did I at Motley Fool
Feb-18-17 05:41PM  Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc. at Motley Fool
07:01AM  The Best Investments for an IRA at Motley Fool
05:53AM  Roche says Phase II trial supports twin treatment for kidney cancer Reuters
Feb-17-17 06:41PM  Momenta Pharma shares halted as drug application hits speed bump at MarketWatch
05:01PM  Trade or fade this week's Dow winners?
04:31PM  AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink
12:00PM  New Data in Crohns Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a Business Wire
08:13AM  Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
07:21AM  Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ
07:05AM  Santhera opens Mass. office as local Duchenne ecosystem grows at bizjournals.com
Feb-16-17 06:55PM  Why This Billionaire Just Shelled Out $1.1 Billion on 4 Drug Stocks at Motley Fool
03:57PM  3 Dividend Stocks That Prove Boring Is Beautiful at Motley Fool
12:06PM  David Tepper Invests Heavily in Pharma in 4th Quarter
11:41AM  How Bristol-Myers Squibb and Pfizer Are Winning a Big Brawl in Blood Thinners at Motley Fool
10:46AM  Procter & Gamble, Pfizer Lead Market Gains
09:19AM  Here Comes Pfizer's Powerful Breakout
09:00AM  Washington University to collaborate with Pfizer on drug discovery at bizjournals.com
08:16AM  Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone at MarketWatch
08:00AM  Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab) Business Wire
Feb-15-17 04:01PM  Pfizer, Cisco Push DJIA Higher Wednesday
03:03PM  5 Ways Allergan Can Keep Up Momentum
02:18PM  Tepper's Appaloosa triples stake in Allergan
12:38PM  Bristol-Myers: Don't Bet on a Pfizer Acquisition at Barrons.com
09:25AM  4 High-Yield Dividend Stocks You Don't Have to Babysit at Motley Fool
08:06AM  Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip
Feb-14-17 05:32PM  David Tepper Increases Wagers on Drug Companies at The Wall Street Journal
03:33PM  Bristol-Myers Squibb: Takeover Target? at Barrons.com
12:49PM  Investing Rookie? Start With These 3 Stocks at Motley Fool
10:45AM  Three Stocks To Buy For Valentines Day at Insider Monkey
09:30AM  The Zacks Analyst Blog Highlights: Boeing, Pfizer, Goldman Sachs, NVIDIA and Twitter
12:25AM  Luxury, lingerie and...Viagra?
Feb-13-17 05:11PM  Allergan To Acquire ZELTIQ in $2.47 Billion Deal, ZELTIQ Shares Pop 13%
02:19PM  Q4 Scorecard & Analyst Reports for Pfizer, Boeing & Goldman Sachs
02:05PM  Lets just call it an American Rally, OK? at MarketWatch
08:00AM  3 Stocks You Can Still Buy With the Market at Record Highs at Motley Fool
Feb-12-17 10:10PM  US issuers rush to sell Formosa bonds before rule change Reuters
Feb-10-17 12:00PM  Is More Downside Ahead For Teva Pharmaceutical? at Barrons.com
11:09AM  Actinium Pharmaceuticals (ATNM) has Considerable Potential in 2017
08:35AM  Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?
Feb-09-17 12:00PM  Academics call time on $100,000 cancer drugs Reuters
08:50AM  10 Best Dividend-Paying Stocks for 2017 at Kiplinger
08:30AM  Relationship Expert Teams Up with Pfizer to Address Intimacy and Relationship Issues for People Living with Chronic Diseases Business Wire
Feb-08-17 06:54PM  Pfizer Builds Consumer Apps to Improve Patient Care at The Wall Street Journal
02:30PM  Pfizer Inc. Value Analysis (NYSE:PFE) : February 8, 2017
02:10PM  3 Greater Washington biotech execs sign industry letter opposing the Trump travel ban at bizjournals.com
01:30PM  4 Dow Stocks Every Retiree Should Own at Kiplinger
01:28PM  Gilead: Where's the Bottom? at Barrons.com
09:48AM  [$$] Sanofi points to lower profit for 2017 at Financial Times
Feb-07-17 12:28PM  Pfizer Inc. (PFE) And Citibank To Work Together On $5 Billion Share Repurchase Program at Insider Monkey
07:22AM  Pfizer Inc. breached its 50 day moving average in a Bullish Manner : PFE-US : February 7, 2017
Feb-06-17 12:56PM  Pfizer CEO: 'Misinformation About Drug Pricing Is Far Greater Than I've Ever Seen'
09:55AM  Q4 Earnings Faring Well for Pharma ETFs
09:30AM  The Zacks Analyst Blog Highlights: Apple, Exxon Mobil, Merck, Pfizer and Intel
08:15AM  Blog Coverage Pfizer Signs Agreement with Citibank to Repurchase $5 Billion Worth of Shares Accesswire
07:45AM  ICU Medical Completes the Acquisition of Hospira Infusion Systems from Pfizer GlobeNewswire
Feb-04-17 06:41AM  Pfizer's New Biosimilar Is Off and Running at Motley Fool
Feb-03-17 01:00PM  MACD: Learn to Recognize Trade Setups
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, Transgene S.A., Edelris SAS, IGNITE Immunotherapy Inc., and AbCellera Biologics Inc.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 07Option Exercise25.8730,000776,100167,687Dec 08 09:48 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 09Sale33.0010,000330,000112,087Nov 10 07:44 PM
BOURLA ALBERTGroup PresidentNov 04Option Exercise24.9920,000499,800149,199Nov 07 05:58 PM
BOURLA ALBERTGroup PresidentNov 04Sale30.0518,390552,530130,809Nov 07 05:58 PM
HILL CHARLES HExecutive Vice PresidentNov 03Option Exercise21.0353,9181,133,896115,033Nov 07 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 02Option Exercise21.0332,545684,421122,087Nov 04 04:36 PM
DAMELIO FRANK AExecutive Vice PresidentMay 26Option Exercise24.43100,0002,443,000472,994May 27 11:03 AM
DAMELIO FRANK AExecutive Vice PresidentMay 26Sale34.49100,0003,449,115372,994May 27 11:03 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Option Exercise25.8786,0002,224,820271,663May 26 10:07 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Sale33.9786,0002,921,147185,663May 26 10:07 AM
YOUNG JOHN DGroup PresidentMay 10Option Exercise25.8741,7001,078,779200,399May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Option Exercise24.43192,0004,690,560564,994May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Sale33.66192,0006,462,579372,994May 11 06:04 PM
YOUNG JOHN DGroup PresidentMay 10Sale33.5341,7001,398,277158,699May 11 06:04 PM
READ IAN CChairman & CEOMay 09Option Exercise25.74275,0007,078,2501,471,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Option Exercise22.2823,884532,136199,735May 11 04:35 PM
HILL CHARLES HExecutive Vice PresidentMay 09Sale33.8429,6001,001,65160,828May 11 04:35 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Sale33.7167,8842,288,669131,851May 11 04:35 PM
READ IAN CChairman & CEOMay 09Sale33.80275,0009,295,0391,196,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 05Option Exercise22.2856,0161,248,036231,867May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 05Sale33.7156,0161,888,144175,851May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Option Exercise22.2820,100447,828195,951May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Sale33.8720,100680,762175,851May 06 09:51 AM
DAMELIO FRANK AExecutive Vice PresidentMay 03Sale33.6587,0792,930,208372,994May 05 05:27 PM